Thomas Gad Sells 4,000 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Share on StockTwits

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $22.40, for a total value of $89,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Thomas Gad also recently made the following trade(s):

  • On Monday, June 24th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $21.77, for a total value of $87,080.00.
  • On Monday, June 10th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.79, for a total value of $91,160.00.
  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.21, for a total value of $121,260.00.
  • On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.61, for a total value of $123,660.00.
  • On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $25.89, for a total value of $6,472,500.00.

Shares of NASDAQ:YMAB opened at $22.71 on Friday. The company has a market capitalization of $784.41 million and a P/E ratio of -15.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30. Y-mAbs Therapeutics, Inc has a 1 year low of $15.17 and a 1 year high of $31.00. The firm’s fifty day simple moving average is $21.79.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). On average, sell-side analysts expect that Y-mAbs Therapeutics, Inc will post -1.95 EPS for the current year.

Large investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in Y-mAbs Therapeutics by 32.2% in the fourth quarter. FMR LLC now owns 1,626,642 shares of the company’s stock valued at $33,086,000 after acquiring an additional 396,000 shares during the period. Millennium Management LLC lifted its holdings in Y-mAbs Therapeutics by 20.9% in the fourth quarter. Millennium Management LLC now owns 386,919 shares of the company’s stock valued at $7,870,000 after acquiring an additional 67,013 shares during the period. BlackRock Inc. lifted its holdings in Y-mAbs Therapeutics by 2,178.9% in the fourth quarter. BlackRock Inc. now owns 341,831 shares of the company’s stock valued at $6,952,000 after acquiring an additional 326,831 shares during the period. Geode Capital Management LLC bought a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $1,587,000. Finally, Northern Trust Corp bought a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $1,533,000. 24.80% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently commented on YMAB. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. Zacks Investment Research cut Yatra Online from a “hold” rating to a “sell” rating in a research note on Saturday, July 6th. Finally, Cowen reissued a “buy” rating on shares of Ovid Therapeutics in a research note on Monday, July 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $30.80.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: What are the advantages to having securities held in street name?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.